Ignet

Gene Information

Gene symbol: CR1

Gene name: complement component (3b/4b) receptor 1 (Knops blood group)

HGNC ID: 2334

Synonyms: CD35, KN

Related Genes

#	Gene Symbol	Number of hits
1	ACTB	1 hits
2	ACTC1	1 hits
3	C3AR1	1 hits
4	C4A	1 hits
5	C4B	1 hits
6	C5AR1	1 hits
7	CD24	1 hits
8	CD46	1 hits
9	CD55	1 hits
10	CD59	1 hits
11	CFH	1 hits
12	CHKA	1 hits
13	COL1A1	1 hits
14	CR2	1 hits
15	CSF1	1 hits
16	CX3CL1	1 hits
17	CXCR4	1 hits
18	DMN	1 hits
19	DPP4	1 hits
20	ELA2	1 hits
21	HLA-A	1 hits
22	ITGAM	1 hits
23	ITGAX	1 hits
24	ITGB2	1 hits
25	MME	1 hits
26	NES	1 hits
27	NPHS2	1 hits
28	PODXL	1 hits
29	PSMD9	1 hits
30	PTPRO	1 hits
31	SYNPO	1 hits
32	TDGF3	1 hits
33	TDGF4	1 hits
34	TNF	1 hits
35	VEGFA	1 hits
36	VIM	1 hits
37	WT1	1 hits

Related Sentences

#	PMID	Sentence
1	1692563	Using an indirect immunoperoxidase technique, we tested frozen specimens from 12 Wilms' tumors with monoclonal antibodies (MoAbs) reacting against a large panel of molecules including laminin, fibronectin, cytokeratin, vimentin, villin, CD24, CALLA/CD10, CR1, CD26, class I and class II major histocompatibility complex (MHC) molecules, and endothelium factor VIII.
2	1692563	Some tubular formations showed signs of proximal maturation with the presence of CALLA, CD26, and even villin.
3	1692563	Large cystic cavities present in five cases were edged by cytokeratin, CD24-positive cells, or by vimentin, CALLA, CR1-positive cells.
4	1692563	Some glomeruloid bodies, present in two cases, were also composed of vimentin, CALLA, and CR1-positive cells which correspond to the mature podocyte phenotype.
5	1692563	The presence of large cells with muscular differentiation was noted; round vimentin and CD26-positive cells were also seen.
6	1692563	The endothelial cells of the vessels exhibited vimentin, factor VIII, and class I and class II MHC molecules as do mature cells, but in some cases the endothelial cells lacked class II molecule expression and were CALLA-positive.
7	1692563	Moreover, this study shows that tumoral cells in nephroblastoma share several antigens with cells from lymphoid lineage (CD24, CALLA, and CD26) as do developing and mature kidney cells.
8	1692563	Using an indirect immunoperoxidase technique, we tested frozen specimens from 12 Wilms' tumors with monoclonal antibodies (MoAbs) reacting against a large panel of molecules including laminin, fibronectin, cytokeratin, vimentin, villin, CD24, CALLA/CD10, CR1, CD26, class I and class II major histocompatibility complex (MHC) molecules, and endothelium factor VIII.
9	1692563	Some tubular formations showed signs of proximal maturation with the presence of CALLA, CD26, and even villin.
10	1692563	Large cystic cavities present in five cases were edged by cytokeratin, CD24-positive cells, or by vimentin, CALLA, CR1-positive cells.
11	1692563	Some glomeruloid bodies, present in two cases, were also composed of vimentin, CALLA, and CR1-positive cells which correspond to the mature podocyte phenotype.
12	1692563	The presence of large cells with muscular differentiation was noted; round vimentin and CD26-positive cells were also seen.
13	1692563	The endothelial cells of the vessels exhibited vimentin, factor VIII, and class I and class II MHC molecules as do mature cells, but in some cases the endothelial cells lacked class II molecule expression and were CALLA-positive.
14	1692563	Moreover, this study shows that tumoral cells in nephroblastoma share several antigens with cells from lymphoid lineage (CD24, CALLA, and CD26) as do developing and mature kidney cells.
15	1692563	Using an indirect immunoperoxidase technique, we tested frozen specimens from 12 Wilms' tumors with monoclonal antibodies (MoAbs) reacting against a large panel of molecules including laminin, fibronectin, cytokeratin, vimentin, villin, CD24, CALLA/CD10, CR1, CD26, class I and class II major histocompatibility complex (MHC) molecules, and endothelium factor VIII.
16	1692563	Some tubular formations showed signs of proximal maturation with the presence of CALLA, CD26, and even villin.
17	1692563	Large cystic cavities present in five cases were edged by cytokeratin, CD24-positive cells, or by vimentin, CALLA, CR1-positive cells.
18	1692563	Some glomeruloid bodies, present in two cases, were also composed of vimentin, CALLA, and CR1-positive cells which correspond to the mature podocyte phenotype.
19	1692563	The presence of large cells with muscular differentiation was noted; round vimentin and CD26-positive cells were also seen.
20	1692563	The endothelial cells of the vessels exhibited vimentin, factor VIII, and class I and class II MHC molecules as do mature cells, but in some cases the endothelial cells lacked class II molecule expression and were CALLA-positive.
21	1692563	Moreover, this study shows that tumoral cells in nephroblastoma share several antigens with cells from lymphoid lineage (CD24, CALLA, and CD26) as do developing and mature kidney cells.
22	1963193	Using an indirect immunoperoxidase technique, we tested frozen specimens from one Wilms' tumour composed of numerous glomeruloid bodies devoid of blood vessels, with monoclonal antibodies directed against vimentin, cytokeratin, CALLA/CD10, CD24, CR1/CD35, endothelium factor VIII, class I and II MHC molecules, laminin, fibronectin, and non-collagenic domain NC1 of type IV collagen.
23	1963193	Glomeruloid bodies comprised two cell types: a peripheral layer of parietal epithelial cells (cytokeratin and CD24-positive) and central cell clumps of podocytes (vimentin and CALLA-positive).
24	2418113	Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor.
25	2418113	The functional and immunochemical characteristics of the human glomerular C3 receptor were investigated by adherence of sheep erythrocytes (Es) coated with defined C3 fragments and by using polyclonal and/or monoclonal antibodies directed against epitopes expressed on complement receptors CR1, CR2, and CR3.
26	2418113	Glomerular CR1 shares the functional antigenic and biochemical properties of the C3b/C4b CR1 receptor of peripheral blood cells.
27	2418113	Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor.
28	2418113	The functional and immunochemical characteristics of the human glomerular C3 receptor were investigated by adherence of sheep erythrocytes (Es) coated with defined C3 fragments and by using polyclonal and/or monoclonal antibodies directed against epitopes expressed on complement receptors CR1, CR2, and CR3.
29	2418113	Glomerular CR1 shares the functional antigenic and biochemical properties of the C3b/C4b CR1 receptor of peripheral blood cells.
30	2418113	Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor.
31	2418113	The functional and immunochemical characteristics of the human glomerular C3 receptor were investigated by adherence of sheep erythrocytes (Es) coated with defined C3 fragments and by using polyclonal and/or monoclonal antibodies directed against epitopes expressed on complement receptors CR1, CR2, and CR3.
32	2418113	Glomerular CR1 shares the functional antigenic and biochemical properties of the C3b/C4b CR1 receptor of peripheral blood cells.
33	2665812	The C3b/C4b complement receptor (CR1) is a large, single-chain integral membrane glycoprotein present on erythrocytes, leukocytes, glomerular podocytes, and splenic dendritic-reticular cells that mediates the binding of complement-coated particles and immune complexes.
34	2941021	Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus.
35	2941021	The expression of CR1 correlated with that of CR2 among patients (r = 0.63; P less than 0.01) but not with the expression of CR2 among normal individuals (r = 0.36; P greater than 0.1).
36	2941021	Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus.
37	2941021	The expression of CR1 correlated with that of CR2 among patients (r = 0.63; P less than 0.01) but not with the expression of CR2 among normal individuals (r = 0.36; P greater than 0.1).
38	2989379	Human complement receptors for C3b (CR1) and C3d (CR2).
39	6223755	The complement receptor for C3b of the epithelial cells of human glomeruli is structurally and functionally very similar or identical to CR1, the complement receptor for C3b and C4b present on the membrane of red cells and leukocytes.
40	6227098	The factor H-like cofactor activity of the C3b receptor promotes the cleavage of bound C3b to iC3b, C3c and C3d, g, reactions that may enhance the clearance of circulating immune complexes and the generation of ligands for CR2 and CR3.
41	7743666	Participation of CR1 (CD35), CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in membranoproliferative glomerulonephritis type I.
42	7743666	The numbers of CR3 (CD11b/CD18)- and CR4 (CD11c/CD18)-positive cells per glomerular cross-section were counted.
43	7743666	At the 1st Bx, no significant difference was found in the number of CR3+ or CR4+ cells between the two groups.
44	7743666	At the 2nd Bx, the numbers of both the CR3+ and CR4+ cells were significantly decreased only in group A (P < 0.01).
45	7743666	The numbers of CR3+ and CR4+ cells were significantly higher in cases with moderate or marked C3c deposits than in those with no or mild C3c deposits.
46	7743666	This irreversible decrease or loss of CR1 may partly contribute to the continuous C3c deposition and intraglomerular infiltration of CR3+ and CR4+ cells.
47	7743666	Participation of CR1 (CD35), CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in membranoproliferative glomerulonephritis type I.
48	7743666	The numbers of CR3 (CD11b/CD18)- and CR4 (CD11c/CD18)-positive cells per glomerular cross-section were counted.
49	7743666	At the 1st Bx, no significant difference was found in the number of CR3+ or CR4+ cells between the two groups.
50	7743666	At the 2nd Bx, the numbers of both the CR3+ and CR4+ cells were significantly decreased only in group A (P < 0.01).
51	7743666	The numbers of CR3+ and CR4+ cells were significantly higher in cases with moderate or marked C3c deposits than in those with no or mild C3c deposits.
52	7743666	This irreversible decrease or loss of CR1 may partly contribute to the continuous C3c deposition and intraglomerular infiltration of CR3+ and CR4+ cells.
53	7957565	Incubation of PMN with formyl-methionyl-leucyl-phenylalanine, tumor necrosis factor-alpha or lipopolysaccharide accelerated the release of soluble CR1, and incubation with granulocyte/macrophage colony-stimulating factor resulted in sustained CR1 gene expression and higher total soluble CR1 release.
54	9551398	Immunohistochemistry identified normal podocyte phenotypes by podocalyxin, vimentin and complement receptor 1 (CR1) labeling.
55	9551398	In collapsed glomeruli, podocalyxin, vimentin and CR1 labeling tagged both normal and vacuolated podocytes still attached to the GBM, but labeling was not found in cobblestone-like podocytes or in podocytes detached from the GBM.
56	9551398	Immunohistochemistry identified normal podocyte phenotypes by podocalyxin, vimentin and complement receptor 1 (CR1) labeling.
57	9551398	In collapsed glomeruli, podocalyxin, vimentin and CR1 labeling tagged both normal and vacuolated podocytes still attached to the GBM, but labeling was not found in cobblestone-like podocytes or in podocytes detached from the GBM.
58	9811343	To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the cyclin-dependent kinase inhibitors (CKIs) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
59	9811343	In S-shaped body stage, Ki-67, a cell proliferation marker that labels the G1/S/G2/M phase, was expressed in the majority (more than 80%) of presumptive podocytes, along with cyclin A (approximately 20% of the Ki-67-positive cells) and cyclin B1 (less than 5% of Ki-67-positive cells) expression.
60	9811343	Among these cells), cyclin D1 and CKIs were markedly down-regulated.
61	9811343	At the capillary-loop stage, by contrast, CKIs and cyclin D1 were intensely positive in podocytes, whereas no Ki-67, cyclin B1, or cyclin A expression was seen.
62	9811343	Moreover, double-immunolabeling and serial-section analysis provided evidence that CKIs and markers specific for differentiating podocytes, namely PHM-5 (podocalyxin-like protein in humans), synaptopodin (a foot process-related protein), and C3b receptor, were co-expressed at the capillary-loop stage.
63	9811343	Furthermore, bcl-2 (an apoptosis inhibitory protein) showed a reciprocal expression pattern to that of CKI.
64	9844117	Decay accelerating factor (DAF), membrane cofactor protein (MCP), and complement receptor type 1 (CR1) act by inactivating C3/C5 convertase.
65	9844117	DAF, MCP, and CD59 are ubiquitously expressed by all three resident glomerular cells, while CR1 is localized exclusively in podocytes.
66	9844117	Decay accelerating factor (DAF), membrane cofactor protein (MCP), and complement receptor type 1 (CR1) act by inactivating C3/C5 convertase.
67	9844117	DAF, MCP, and CD59 are ubiquitously expressed by all three resident glomerular cells, while CR1 is localized exclusively in podocytes.
68	9890309	The differentiation of podocytes coincides with progressive expression of maturity markers, including WT-1, CALLA, C3b receptor, GLEPP-1, podocalyxin, and synaptopodin.
69	10352206	Thus, CR1, the most efficient cell-bound cofactor for the inactivation of C4b/C3b by factor I, appears to be consumed when factor I is missing.
70	10556832	Purified human neutrophil elastase (HNE) cleaved CR1 from erythrocytes and urinary vesicles originating from podocytes and enhanced tenfold the cleavage of CR1 from activated PMN.
71	10556832	The largest fragment released from PMN by HNE was identical in size to CR1 shed spontaneously.
72	10556832	Purified human neutrophil elastase (HNE) cleaved CR1 from erythrocytes and urinary vesicles originating from podocytes and enhanced tenfold the cleavage of CR1 from activated PMN.
73	10556832	The largest fragment released from PMN by HNE was identical in size to CR1 shed spontaneously.
74	11095009	Complement homologous restriction factor CD59 and complement receptor CD35 are typically involved in the regulation of the host defense system.
75	11095009	Recent observations in the human fetal kidney suggest a further role for complement cell surface regulators CD35 and CD59 in kidney development and maturation.
76	11095009	We investigated this possible role by localizing CD35 and CD59 protein and mRNA in the developing and adult kidney.
77	11095009	The specific spatial and temporal expression of CD35 and CD59 suggests a possible role for these complement regulatory proteins in renal cell differentiation.
78	11095009	Complement homologous restriction factor CD59 and complement receptor CD35 are typically involved in the regulation of the host defense system.
79	11095009	Recent observations in the human fetal kidney suggest a further role for complement cell surface regulators CD35 and CD59 in kidney development and maturation.
80	11095009	We investigated this possible role by localizing CD35 and CD59 protein and mRNA in the developing and adult kidney.
81	11095009	The specific spatial and temporal expression of CD35 and CD59 suggests a possible role for these complement regulatory proteins in renal cell differentiation.
82	11095009	Complement homologous restriction factor CD59 and complement receptor CD35 are typically involved in the regulation of the host defense system.
83	11095009	Recent observations in the human fetal kidney suggest a further role for complement cell surface regulators CD35 and CD59 in kidney development and maturation.
84	11095009	We investigated this possible role by localizing CD35 and CD59 protein and mRNA in the developing and adult kidney.
85	11095009	The specific spatial and temporal expression of CD35 and CD59 suggests a possible role for these complement regulatory proteins in renal cell differentiation.
86	11095009	Complement homologous restriction factor CD59 and complement receptor CD35 are typically involved in the regulation of the host defense system.
87	11095009	Recent observations in the human fetal kidney suggest a further role for complement cell surface regulators CD35 and CD59 in kidney development and maturation.
88	11095009	We investigated this possible role by localizing CD35 and CD59 protein and mRNA in the developing and adult kidney.
89	11095009	The specific spatial and temporal expression of CD35 and CD59 suggests a possible role for these complement regulatory proteins in renal cell differentiation.
90	11158216	Immunohistochemistry and confocal laser microscopy carried out on kidneys with FSGS relapse disclosed several phenomena. (1) Some podocytes that expressed podocalyxin, synaptopodin, and glomerular epithelial protein-1 were detached from the tuft and were free in the urinary space. (2) In the cellular variant, most podocytes had lost podocyte-specific epitopes (podocalyxin, synaptopodin, glomerular epithelial protein-1, Wilm's tumor protein-1, complement receptor-1, and vimentin).
91	11158216	In the scar variant, these podocyte markers were absent from cobblestone-like epithelial cells and from pseudotubules. (3) Podocytes had acquired expression of various cytokeratins (CK; identified by the AE1/AE3, C2562, CK22, and AEL-KS2 monoclonal antibodies) that were not found in the podocytes of control glomeruli.
92	11158216	Parietal epithelial cells expressed AE1/AE3 CK that were faintly, if ever, found on the parietal epithelial cells of normal glomeruli. (4) Numerous cells located at the periphery of the tuft or free in Bowman's space and within tubular lumens expressed macrophagic epitopes (identified by PGM1 [CD68], HAM56, and 25F9 monoclonal antibodies).
93	11158216	These macrophage-like cells expressed the activation epitopes HLA-DR and CD16. (5) A number of these cells coexpressed podocalyxin + AE1/AE3 CK, podocalyxin + CD68, and CD68 + AE1/AE3.
94	12955485	Insulin-like growth factor binding protein-2 modulates podocyte mitogenesis.
95	12955485	To study the role of insulin-like growth factors (IGF) in podocyte maturation, we isolated and characterized fetal visceral glomerular epithelial cells from human kidneys obtained at 8-18 weeks gestation.
96	12955485	Cells were identified as podocyte lineage by their cobblestone morphology and immunoreactivity with synaptopodin, Wilms tumor-1 suppressor gene product (WT-1), complement receptor CR1, and cytoskeletal proteins smooth muscle actin and vimentin.
97	12955485	Stimulation of the podocyte cell monolayers with IGF-II resulted in a slight increase in mitogenesis, an effect that was concentration and time dependent and abrogated by co-incubation with exogenous IGF binding protein 2 (IGFBP-2).
98	12955485	IGF-II stimulation enhanced IGFBP-2 production in a dose- and time-dependent fashion and was associated with an increase in IGFBP-2 mRNA production.
99	12955485	These data demonstrate that IGF-II-stimulated IGFBP-2 production appears to inhibit the mitogenic effect of IGF-II, and may have an autocrine effect on the maturation, differentiation, and survival of fetal podocytes.
100	14556965	The human complement receptor 1 (C3b/C4b receptor, CD35, CR1), a polymorphic membrane bound glycoprotein, is differentially expressed on erythrocytes, eosinophils, monocytes, B and T-lymphocytes, dendritic cells and kidney podocytes.
101	15072851	Association of complement receptor 1 (CR1, CD35, C3b/C4b receptor) density polymorphism with glomerulonephritis in Indian subjects.
102	15072851	Complement receptor 1 (CR1, CD35, C3b/C4b receptor), a polymorphic membrane bound glycoprotein is important both as a complement regulatory protein, and as a vehicle for immune complex clearance.
103	15072851	Association of complement receptor 1 (CR1, CD35, C3b/C4b receptor) density polymorphism with glomerulonephritis in Indian subjects.
104	15072851	Complement receptor 1 (CR1, CD35, C3b/C4b receptor), a polymorphic membrane bound glycoprotein is important both as a complement regulatory protein, and as a vehicle for immune complex clearance.
105	15163541	For RT-PCR, ratio of CR1/beta-actin was considered for semiquantitation of the level of CR1 transcription.
106	15864913	Recently, reduced leukocytes CR1 gene transcription had been demonstrated in SLE and was suggested as the main cause of decline in leukocyte CR1 (L-CR1).
107	16919753	In the rodent, CFH on platelets functions as the immune adherence receptor, analogous to CR1 on primate erythrocytes.
108	16919753	The same switch also appears to be true in the rodent podocyte where CFH is present in place of CR1 in human podocytes.
109	16919753	In the rodent, CFH on platelets functions as the immune adherence receptor, analogous to CR1 on primate erythrocytes.
110	16919753	The same switch also appears to be true in the rodent podocyte where CFH is present in place of CR1 in human podocytes.
111	17344423	Mouse podocyte complement factor H: the functional analog to human complement receptor 1.
112	17344423	It was shown that rodent Cfh on platelets is the functional analogue to human erythrocyte complement receptor 1 with a role that is distinct from plasma Cfh and that Cfh is also on cultured rodent podocytes.
113	17344423	Just as in platelets, rodent podocytes seem to use Cfh as the functional surrogate for human complement receptor 1.
114	17344423	Mouse podocyte complement factor H: the functional analog to human complement receptor 1.
115	17344423	It was shown that rodent Cfh on platelets is the functional analogue to human erythrocyte complement receptor 1 with a role that is distinct from plasma Cfh and that Cfh is also on cultured rodent podocytes.
116	17344423	Just as in platelets, rodent podocytes seem to use Cfh as the functional surrogate for human complement receptor 1.
117	17344423	Mouse podocyte complement factor H: the functional analog to human complement receptor 1.
118	17344423	It was shown that rodent Cfh on platelets is the functional analogue to human erythrocyte complement receptor 1 with a role that is distinct from plasma Cfh and that Cfh is also on cultured rodent podocytes.
119	17344423	Just as in platelets, rodent podocytes seem to use Cfh as the functional surrogate for human complement receptor 1.
120	17533009	There is mounting evidence that intrinsic glomerular and tubular cell C3aR and C5aR expression and activation also can affect renal injury.
121	17533009	CR1 on podocytes and the beta2 integrins CR3 and CR4 in kidney dendritic cells have functions that remain poorly defined.
122	17533009	Thus, intrinsic renal cells express decay-accelerating factor, membrane cofactor protein, Crry, C3aR, C5aR, CR1, CR3, and CR4.
123	17533009	There is mounting evidence that intrinsic glomerular and tubular cell C3aR and C5aR expression and activation also can affect renal injury.
124	17533009	CR1 on podocytes and the beta2 integrins CR3 and CR4 in kidney dendritic cells have functions that remain poorly defined.
125	17533009	Thus, intrinsic renal cells express decay-accelerating factor, membrane cofactor protein, Crry, C3aR, C5aR, CR1, CR3, and CR4.
126	20369732	CR1 is a receptor for C3b and C4b and plays an important role in the removal of immune complexes coated with C3b and C4b.
127	20369733	CR1 (Complement Receptor 1, CD35) is a membrane receptor for C3b and C4b expressed on erythrocytes, leukocytes and podocytes.
128	20495534	Immunohistochemistry was applied to detect the expression of nestin, cell-cycle regulatory protein p27, as well as complement C5b-9 and complement receptor 1 (CR1).
129	20495534	Compared with the Control, IgAN glomeruli had reduced podocyte expression of p27 and nestin along with decreased podocyte number.
130	20702729	Complement receptor 1 (CR1) on human erythrocytes (Es) and complement factor H (CFH) on rodent platelets perform immune adherence, which is a function that allows the processing of immune complexes (ICs) bearing C3 by the mononuclear phagocyte system.
131	20702729	Similar immune adherence occurs in the glomerular podocyte by CR1 in humans and CFH in rodents.
132	20702729	As a model for human IC processing, we studied transgenic mice lacking CFH systemically but with human CR1 on Es.
133	20702729	These CR1(hu)Tg/CFH(-/-) mice spontaneously developed proliferative glomerulonephritis, which was accelerated in a chronic serum sickness model by active immunization with heterologous apoferritin.
134	20702729	ICs containing Ag, IgG and C3 bound to Es in CR1(hu)Tg/CFH(-/-) mice.
135	20702729	In this setting, there was increased IC deposition in glomeruli, attributable to the presence of CR1 on Es, together with the absence of CFH on platelets and podocytes.
136	20702729	Complement receptor 1 (CR1) on human erythrocytes (Es) and complement factor H (CFH) on rodent platelets perform immune adherence, which is a function that allows the processing of immune complexes (ICs) bearing C3 by the mononuclear phagocyte system.
137	20702729	Similar immune adherence occurs in the glomerular podocyte by CR1 in humans and CFH in rodents.
138	20702729	As a model for human IC processing, we studied transgenic mice lacking CFH systemically but with human CR1 on Es.
139	20702729	These CR1(hu)Tg/CFH(-/-) mice spontaneously developed proliferative glomerulonephritis, which was accelerated in a chronic serum sickness model by active immunization with heterologous apoferritin.
140	20702729	ICs containing Ag, IgG and C3 bound to Es in CR1(hu)Tg/CFH(-/-) mice.
141	20702729	In this setting, there was increased IC deposition in glomeruli, attributable to the presence of CR1 on Es, together with the absence of CFH on platelets and podocytes.
142	20702729	Complement receptor 1 (CR1) on human erythrocytes (Es) and complement factor H (CFH) on rodent platelets perform immune adherence, which is a function that allows the processing of immune complexes (ICs) bearing C3 by the mononuclear phagocyte system.
143	20702729	Similar immune adherence occurs in the glomerular podocyte by CR1 in humans and CFH in rodents.
144	20702729	As a model for human IC processing, we studied transgenic mice lacking CFH systemically but with human CR1 on Es.
145	20702729	These CR1(hu)Tg/CFH(-/-) mice spontaneously developed proliferative glomerulonephritis, which was accelerated in a chronic serum sickness model by active immunization with heterologous apoferritin.
146	20702729	ICs containing Ag, IgG and C3 bound to Es in CR1(hu)Tg/CFH(-/-) mice.
147	20702729	In this setting, there was increased IC deposition in glomeruli, attributable to the presence of CR1 on Es, together with the absence of CFH on platelets and podocytes.
148	20702729	Complement receptor 1 (CR1) on human erythrocytes (Es) and complement factor H (CFH) on rodent platelets perform immune adherence, which is a function that allows the processing of immune complexes (ICs) bearing C3 by the mononuclear phagocyte system.
149	20702729	Similar immune adherence occurs in the glomerular podocyte by CR1 in humans and CFH in rodents.
150	20702729	As a model for human IC processing, we studied transgenic mice lacking CFH systemically but with human CR1 on Es.
151	20702729	These CR1(hu)Tg/CFH(-/-) mice spontaneously developed proliferative glomerulonephritis, which was accelerated in a chronic serum sickness model by active immunization with heterologous apoferritin.
152	20702729	ICs containing Ag, IgG and C3 bound to Es in CR1(hu)Tg/CFH(-/-) mice.
153	20702729	In this setting, there was increased IC deposition in glomeruli, attributable to the presence of CR1 on Es, together with the absence of CFH on platelets and podocytes.
154	20702729	Complement receptor 1 (CR1) on human erythrocytes (Es) and complement factor H (CFH) on rodent platelets perform immune adherence, which is a function that allows the processing of immune complexes (ICs) bearing C3 by the mononuclear phagocyte system.
155	20702729	Similar immune adherence occurs in the glomerular podocyte by CR1 in humans and CFH in rodents.
156	20702729	As a model for human IC processing, we studied transgenic mice lacking CFH systemically but with human CR1 on Es.
157	20702729	These CR1(hu)Tg/CFH(-/-) mice spontaneously developed proliferative glomerulonephritis, which was accelerated in a chronic serum sickness model by active immunization with heterologous apoferritin.
158	20702729	ICs containing Ag, IgG and C3 bound to Es in CR1(hu)Tg/CFH(-/-) mice.
159	20702729	In this setting, there was increased IC deposition in glomeruli, attributable to the presence of CR1 on Es, together with the absence of CFH on platelets and podocytes.
160	20702729	Complement receptor 1 (CR1) on human erythrocytes (Es) and complement factor H (CFH) on rodent platelets perform immune adherence, which is a function that allows the processing of immune complexes (ICs) bearing C3 by the mononuclear phagocyte system.
161	20702729	Similar immune adherence occurs in the glomerular podocyte by CR1 in humans and CFH in rodents.
162	20702729	As a model for human IC processing, we studied transgenic mice lacking CFH systemically but with human CR1 on Es.
163	20702729	These CR1(hu)Tg/CFH(-/-) mice spontaneously developed proliferative glomerulonephritis, which was accelerated in a chronic serum sickness model by active immunization with heterologous apoferritin.
164	20702729	ICs containing Ag, IgG and C3 bound to Es in CR1(hu)Tg/CFH(-/-) mice.
165	20702729	In this setting, there was increased IC deposition in glomeruli, attributable to the presence of CR1 on Es, together with the absence of CFH on platelets and podocytes.
166	23675111	The Comparison of the Podocyte Expression of Synaptopodin, CR1 and Neprilysin in Human Glomerulonephritis: Could the Expression of CR1 be Clinically Relevant?
167	23675111	We compared the expression of three podocyte markers, i.e.: synaptopodin (SYN), CR1 and neprilysin (NEP) in 107 patients with different forms of glomerulonephritis (GN) and 5 normal kidneys (NK).
168	23675111	We observed the reduction in the podocyte expression of NEP, SYN and CR1 in proliferative and non-proliferative forms of GN.
169	23675111	Interestingly, in mesangial proliferative GN (MesPGN), the expression of SYN and CR1 was lower in IgA-MesPGN than in non-IgA-MesPGN (p<0.005 and p<0.02, respectively).
170	23675111	In all the patients, the expression of NEP and SYN was positively related (r=0.53, p=0.02) as that of NEP and CR1 (r=0.39, p=0.04).
171	23675111	In conclusion, SYN, CR1 and NEP may be used as markers of podocyte loss in patients with GN.
172	23675111	The Comparison of the Podocyte Expression of Synaptopodin, CR1 and Neprilysin in Human Glomerulonephritis: Could the Expression of CR1 be Clinically Relevant?
173	23675111	We compared the expression of three podocyte markers, i.e.: synaptopodin (SYN), CR1 and neprilysin (NEP) in 107 patients with different forms of glomerulonephritis (GN) and 5 normal kidneys (NK).
174	23675111	We observed the reduction in the podocyte expression of NEP, SYN and CR1 in proliferative and non-proliferative forms of GN.
175	23675111	Interestingly, in mesangial proliferative GN (MesPGN), the expression of SYN and CR1 was lower in IgA-MesPGN than in non-IgA-MesPGN (p<0.005 and p<0.02, respectively).
176	23675111	In all the patients, the expression of NEP and SYN was positively related (r=0.53, p=0.02) as that of NEP and CR1 (r=0.39, p=0.04).
177	23675111	In conclusion, SYN, CR1 and NEP may be used as markers of podocyte loss in patients with GN.
178	23675111	The Comparison of the Podocyte Expression of Synaptopodin, CR1 and Neprilysin in Human Glomerulonephritis: Could the Expression of CR1 be Clinically Relevant?
179	23675111	We compared the expression of three podocyte markers, i.e.: synaptopodin (SYN), CR1 and neprilysin (NEP) in 107 patients with different forms of glomerulonephritis (GN) and 5 normal kidneys (NK).
180	23675111	We observed the reduction in the podocyte expression of NEP, SYN and CR1 in proliferative and non-proliferative forms of GN.
181	23675111	Interestingly, in mesangial proliferative GN (MesPGN), the expression of SYN and CR1 was lower in IgA-MesPGN than in non-IgA-MesPGN (p<0.005 and p<0.02, respectively).
182	23675111	In all the patients, the expression of NEP and SYN was positively related (r=0.53, p=0.02) as that of NEP and CR1 (r=0.39, p=0.04).
183	23675111	In conclusion, SYN, CR1 and NEP may be used as markers of podocyte loss in patients with GN.
184	23675111	The Comparison of the Podocyte Expression of Synaptopodin, CR1 and Neprilysin in Human Glomerulonephritis: Could the Expression of CR1 be Clinically Relevant?
185	23675111	We compared the expression of three podocyte markers, i.e.: synaptopodin (SYN), CR1 and neprilysin (NEP) in 107 patients with different forms of glomerulonephritis (GN) and 5 normal kidneys (NK).
186	23675111	We observed the reduction in the podocyte expression of NEP, SYN and CR1 in proliferative and non-proliferative forms of GN.
187	23675111	Interestingly, in mesangial proliferative GN (MesPGN), the expression of SYN and CR1 was lower in IgA-MesPGN than in non-IgA-MesPGN (p<0.005 and p<0.02, respectively).
188	23675111	In all the patients, the expression of NEP and SYN was positively related (r=0.53, p=0.02) as that of NEP and CR1 (r=0.39, p=0.04).
189	23675111	In conclusion, SYN, CR1 and NEP may be used as markers of podocyte loss in patients with GN.
190	23675111	The Comparison of the Podocyte Expression of Synaptopodin, CR1 and Neprilysin in Human Glomerulonephritis: Could the Expression of CR1 be Clinically Relevant?
191	23675111	We compared the expression of three podocyte markers, i.e.: synaptopodin (SYN), CR1 and neprilysin (NEP) in 107 patients with different forms of glomerulonephritis (GN) and 5 normal kidneys (NK).
192	23675111	We observed the reduction in the podocyte expression of NEP, SYN and CR1 in proliferative and non-proliferative forms of GN.
193	23675111	Interestingly, in mesangial proliferative GN (MesPGN), the expression of SYN and CR1 was lower in IgA-MesPGN than in non-IgA-MesPGN (p<0.005 and p<0.02, respectively).
194	23675111	In all the patients, the expression of NEP and SYN was positively related (r=0.53, p=0.02) as that of NEP and CR1 (r=0.39, p=0.04).
195	23675111	In conclusion, SYN, CR1 and NEP may be used as markers of podocyte loss in patients with GN.
196	24161042	Activation of the complement system is tightly regulated by plasma and cell-associated complement regulatory proteins (CRPs), such as factor H (fH), decay-accelerating factor, and membrane cofactor protein.
197	24161042	The uniquely rodent protein, CR1-related y (Crry), has features analogous to human membrane cofactor protein.
198	25291704	These receptors, which are termed CR1, CR2 and CR3, reside on lymphocytes, myelomonocytic cells, erythrocytes and renal podocytes.
199	26260209	The deposited C4b and C3b were progressively cleaved with a t½ of ∼ 30 min to C4d and C3d, respectively, by CR1-dependent cofactor activity.
200	26260209	Moreover, CR1 efficiently and stably bound but didn't internalize C4b/C3b opsonized immune complexes.
201	26260209	The deposited C4b and C3b were progressively cleaved with a t½ of ∼ 30 min to C4d and C3d, respectively, by CR1-dependent cofactor activity.
202	26260209	Moreover, CR1 efficiently and stably bound but didn't internalize C4b/C3b opsonized immune complexes.
203	26471127	A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H.
204	26728561	Alport syndrome (AS) is a hereditary glomerulopathy caused by a mutation in type IV collagen genes, which disrupts glomerular basement membrane, leading to progressive glomerulosclerosis and end-stage renal failure.
205	26728561	This was associated with less renal cortical fibrosis and interstitial inflammation compared to nontransplanted mice as shown by reduction in murine CD4, CD68, and CD45.2 cells.
206	26728561	Transplanted CSC homed to glomeruli, where they expressed CR1, VEGFA, SYNAPTOPODIN, CD2AP, and PODOCIN at the RNA level and produced PODOCIN, CD2AP, and COLIVα3 proteins in nontransplanted -/- mice, indicating that CSC have adopted a podocyte phenotype.
207	30207169	The present study determined the role of the fractalkine receptor CX₃CR1 in hypertensive renal and cardiac injury.